Open Access

Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC

  • Authors:
    • Dezhi Li
    • Jie Qin
    • Tao Zhou
    • Yaqin Li
    • Xianyi Cheng
    • Zaizhong Chen
    • Junhui Chen
    • Wei V. Zheng
  • View Affiliations

  • Published online on: March 10, 2023     https://doi.org/10.3892/ijo.2023.5501
  • Article Number: 53
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Constantly stimulated by the tumor microenvironment (TME), programmed death 1 (PD‑1) is elevated, and it interacts with PD ligand 1 (PD‑L1), rendering chimeric antigen receptor (CAR)‑T cells dysfunctional. Hence, CAR‑T cells immune to PD‑1‑induced immunosuppression were constructed to improve the function of CAR‑T cells in hepatocellular carcinoma (HCC). Double‑target CAR‑T cells, targeting glypican‑3 (GPC3) [a tumour-associated antigen (TAA)] and hindering PD‑1‑PD‑L1 binding, were established. The expression of GPC3, PD‑L1, and inhibitory receptors was measured using flow cytometry. The cytotoxicity, cytokine release, and differentiation level of CAR‑T cells were determined using lactate dehydrogenase release assay, enzyme‑linked immunosorbent assay, and flow cytometry, respectively. HCC cells were targeted and eliminated by double‑target CAR‑T cells. These double‑target CAR‑T cells limit PD‑1‑PD‑L1 binding and sustain cytotoxicity to PD‑L1+ HCC cells. The relatively low IR expression and differentiation level in double‑target CAR‑T cells in tumour tissues induced tumour‑suppression and extended survival in PD‑L1+ HCC TX models, as opposed to their single‑target counterparts. The results of the present study suggested that the newly constructed double‑target CAR‑T cells exhibit stronger tumour‑suppressing effects in HCC than their single‑target counterparts, which are common, suggesting the potential of strengthening CAR‑T cell activity in HCC treatment.
View Figures
View References

Related Articles

Journal Cover

April-2023
Volume 62 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li D, Qin J, Zhou T, Li Y, Cheng X, Chen Z, Chen J and Zheng WV: Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC. Int J Oncol 62: 53, 2023
APA
Li, D., Qin, J., Zhou, T., Li, Y., Cheng, X., Chen, Z. ... Zheng, W.V. (2023). Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC. International Journal of Oncology, 62, 53. https://doi.org/10.3892/ijo.2023.5501
MLA
Li, D., Qin, J., Zhou, T., Li, Y., Cheng, X., Chen, Z., Chen, J., Zheng, W. V."Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC". International Journal of Oncology 62.4 (2023): 53.
Chicago
Li, D., Qin, J., Zhou, T., Li, Y., Cheng, X., Chen, Z., Chen, J., Zheng, W. V."Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC". International Journal of Oncology 62, no. 4 (2023): 53. https://doi.org/10.3892/ijo.2023.5501